Replies to post #5681 on Halozyme Therapeutics Inc (HALO)

[Sluicebox]

Thanks,
I think with the recent approvals of DARA combos we will reach $7B in 23/24 with an increase of 1B every year from 3B in 2019. DARA has a real issue with iv-chairs, not sure the approved drugs has, perhaps the approved drugs were going SC-way to try differentiate themselves form the biosimilars/generics. Also the current drugs has a lot less advantage with the SC vs IV compared to DARA IV vs SC. The current approved drugs using Enhanze, all seems very mature whereas DARA is fast increasing sales. So I am hoping DARA SC will grow Enhanze revenues FAST. The million dollar question is JNJ's pricing of DARA SC.